Experimental Hematology & Oncology (Aug 2024)

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities

  • Jing Zhang,
  • Xiaoping Zeng,
  • Qiji Guo,
  • Zhenxin Sheng,
  • Yan Chen,
  • Shiyue Wan,
  • Lele Zhang,
  • Peng Zhang

DOI
https://doi.org/10.1186/s40164-024-00548-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 29

Abstract

Read online

Abstract Small cell lung cancer (SCLC) is a recalcitrant cancer characterized by early metastasis, rapid tumor growth and poor prognosis. In recent decades, the epidemiology, initiation and mutation characteristics of SCLC, as well as abnormal signaling pathways contributing to its progression, have been widely studied. Despite extensive investigation, fewer drugs have been approved for SCLC. Recent advancements in multi-omics studies have revealed diverse classifications of SCLC that are featured by distinct characteristics and therapeutic vulnerabilities. With the accumulation of SCLC samples, different subtypes of SCLC and specific treatments for these subtypes were further explored. The identification of different molecular subtypes has opened up novel avenues for the treatment of SCLC; however, the inconsistent and uncertain classification of SCLC has hindered the translation from basic research to clinical applications. Therefore, a comprehensives review is essential to conclude these emerging subtypes and related drugs targeting specific therapeutic vulnerabilities within abnormal signaling pathways. In this current review, we summarized the epidemiology, risk factors, mutation characteristics of and classification, related molecular pathways and treatments for SCLC. We hope that this review will facilitate the translation of molecular subtyping of SCLC from theory to clinical application.

Keywords